Susan G. Arbuck - Concepedia

Author

Susan G. Arbuck

Also Known As

Anthony J Murgo, S ARBUCK, S Arbuck, S G Arbuck, S. ARBUCK, S. Arbuck, S. G. Arbuck, S.G. Arbuck, SUSAN ARBUCK, SUSAN G. ARBUCK

Publications

52.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Roswell Park Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center National Institutes of Health St. Jude Children's Research Hospital

About

Susan G. Arbuck is an author at National Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	38	47.3K
2	Health Sciences	7	7	45.1K
3	Natural Sciences	2	2	181
4	Allergy	2	2	114
5	Public Health	1	1	48

Susan G. Arbuck

Publications

51.4K

Citations

H-Index

Page 1

	Year	Citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials J I Johnson, Shannon Decker, Daniel Zaharevitz, British Journal of Cancer	2001	850
New guidelines to evaluate the response to treatment in solid tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Breast Cancer Solid TumorsMedicineCancer ManagementNew GuidelinesCancer Treatment	2005	662
Accelerated Titration Designs for Phase I Clinical Trials in Oncology Richard Simon, Larry Rubinstein, Susan G. Arbuck, JNCI Journal of the National Cancer Institute	1997	632
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson, Journal of Clinical Oncology	1998	408
Taxol: the first of the taxanes, an important new class of antitumor agents. Eric K. Rowinsky, Nicole Onetto, Renzo Canetta, PubMed	1992	393
Taxol®: science and applications. M Suffness, Monroe E. Wall, H. R. Hartzell, DerivativesMedicineFine ChemicalDrug DevelopmentPharmacology	1995	336
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann, Journal of Clinical Oncology	2001	294
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Lorina Dudkin, Michael B. Dilling, Pamela J. Cheshire, PubMed Chemoprevention StrategyCancer BiologyTumor BiologyMolecular PharmacologyCancer Cell Biology	2001	232

Page 1